Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 18/20 | 0.45 |
| ▸ | ADORA2A | P29274 | 10/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.45 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1002670 | 0.93 | ADORA2B (0.49) | ADORA2BADORA2AADORA1ADORA3 | |
| SCHEMBL1243367 | 0.91 | ADORA2B (0.46) | ADORA2BADORA2AADORA1ADORA3 | |
| SCHEMBL1243464 | 0.90 | ADORA2B (0.49) | ADORA2BADORA2AADORA1ADORA3 | |
| SCHEMBL9885749 | 0.89 | ADORA2B (0.45) | ADORA2BADORA2AADORA1ADORA3 | |
| SCHEMBL16299181 | 0.88 | ADORA2B (0.46) | ADORA2BADORA2AADORA1ADORA3 | |
| SCHEMBL1242614 | 0.88 | ADORA2B (0.46) | ADORA2BADORA2AADORA1ADORA3 | |
| SCHEMBL1243808 | 0.86 | ADORA2A (0.44) | ADORA2BADORA2AADORA1ADORA3 | |
| SCHEMBL24786686 | 0.86 | ADORA2B (0.41) | ADORA2BADORA2AADORA1ADORA3 | |
| SCHEMBL30073420 | 0.86 | ADORA2B (0.41) | ADORA2BADORA2AADORA1ADORA3 | |
| SCHEMBL24787115 | 0.85 | ADORA2B (0.51) | ADORA2BADORA2AADORA1ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7875608-B2 | selective antagonists of A2B adenosine receptors; 6-Chloro-N-[5-(1-cyclopropyl-2,6-dioxo-3-propyl-2,3,6,7-tetrahydro-1H-purin-8-yl)-pyridin-2-yl]-N-(2-pyridin-2-yl-ethyl)-nicotinamide; for treating asthma, diarrhea, insulin resistance, and diabetic retinopathy | ADENOSINE THERAPEUTICS, LLC | 2011-01-25 | — | — | US | disclosed |
| US-7875608-B2 | selective antagonists of A2B adenosine receptors; 6-Chloro-N-[5-(1-cyclopropyl-2,6-dioxo-3-propyl-2,3,6,7-tetrahydro-1H-purin-8-yl)-pyridin-2-yl]-N-(2-pyridin-2-yl-ethyl)-nicotinamide; for treating asthma, diarrhea, insulin resistance, and diabetic retinopathy | ADENOSINE THERAPEUTICS, LLC | 2011-01-25 | — | — | US | disclosed |
| US-7875608-B2 | selective antagonists of A2B adenosine receptors; 6-Chloro-N-[5-(1-cyclopropyl-2,6-dioxo-3-propyl-2,3,6,7-tetrahydro-1H-purin-8-yl)-pyridin-2-yl]-N-(2-pyridin-2-yl-ethyl)-nicotinamide; for treating asthma, diarrhea, insulin resistance, and diabetic retinopathy | ADENOSINE THERAPEUTICS, LLC | 2011-01-25 | — | — | US | disclosed |
| US-20090163491-A1 | SUBSTITUTED 8-[6-AMINO-3PYRIDYL]XANTHINES | ADENOSINE THERAPEUTICS, LTD. | 2009-06-25 | — | — | US | disclosed |
| US-20090163491-A1 | SUBSTITUTED 8-[6-AMINO-3PYRIDYL]XANTHINES | ADENOSINE THERAPEUTICS, LTD. | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163491-A1 | SUBSTITUTED 8-[6-AMINO-3PYRIDYL]XANTHINES | ADORA2B, ADORA2A, ADORA3 | ADORA2B 1/4885ADORA2A 2/4885ADORA1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.